Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis

NCT ID: NCT01998139

Last Updated: 2020-07-28

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 137 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2019-02-28

Brief Summary

Sepsis is a major global health problem, leading to substantial morbidity and mortality despite medical care. The initial diagnosis of sepsis is a clinical challenge, as it is based on nonspecific systemic criteria. Excessive endothelial activation is a cardinal feature of sepsis and contributes to microvascular leak, edema, circulatory shock and organ failure. Activated endothelial cells shed endothelial microparticles (EMPs) which can be measured in plasma and are found at low levels in healthy subjects. Elevated EMPs have been reported in sepsis, but whether their effect is beneficial or deleterious is unclear. In this context, we hypothesize that circulating EMP levels can be assessed as a biomarker differentiating sepsis from non-sepsis critical illness. This may also suggest that EMP levels correlate with 30-day mortality. We propose to measure circulating EMPs at ICU admission in subjects with suspected sepsis. Final diagnoses will be adjudicated using standard criteria and 30-day mortality ascertained. Subjects determined not to have sepsis will serve as the control group. EMP levels will be correlated with diagnosis to ascertain the utility of EMP levels as a diagnostic biomarker for sepsis. For those subjects with proven sepsis, EMP levels will be correlated to 30-day mortality to assess EMP level as a prognostic marker in sepsis.

Detailed Description

In the presence of infection, normal immune and physiologic responses act in concert to eradicate pathogens. When these responses are inappropriately regulated, sepsis develops. Sepsis is characterized by systemic manifestations of infection. The diagnosis is made by identifying at least 2 of the components of the systemic inflammatory response syndrome (SIRS), based on four clinical and laboratory criteria: respiratory rate, tachycardia, temperature, and leukocyte level in the presence of a documented infection. The presence of acute organ dysfunction in this setting defines severe sepsis, and hypotension that is not reversed with fluid administration defines the entity of septic shock. Severe sepsis as well as its most severe form, septic shock, are significant global health concerns, afflicting millions of patients worldwide, increasing in incidence, and having an associated mortality rate of >25%. In the United States alone, an estimated 750,000 people develop sepsis or severe sepsis each year, and sepsis/septic shock is the 11th leading illness leading to mortality in the US. The annual cost burden of sepsis is estimated to be more than $17 billion. For these reasons, clinical investigators interested in sepsis have directed efforts toward identifying a biomarker that would be useful in making an early diagnosis of sepsis. In addition to early diagnosis, biomarkers for prognosis have been sought to guide severity assessment and to guide more personalized treatment of individual patients.

Endothelial Activation in Sepsis Endothelial activation occurs early in systemic infections and is an adaptive response, allowing leukocyte migration to sites of microbial invasion. In sepsis, however, endothelial activation is excessive and poses the following risks: harm via tissue damage due to excessive leukocyte recruitment, disseminated intravascular coagulation (DIC) relating to loss of endothelial anticoagulant properties, apoptotic death of endothelial cells, and loss of microvascular barrier function. The dysfunctional endothelial barrier leads to vascular leak and tissue edema, hallmarks of sepsis. This loss of endothelial barrier function is linked to increased morbidity and mortality in animal models of sepsis.

Endothelial Microparticles Microparticles are intact vesicles of a size 0.2-2.0 μm which are released from plasma membranes of multiple cell types in the setting of cell injury, activation, and/or apoptosis. In healthy individuals, microparticles found in the plasma are derived from platelets, erythrocytes, leukocytes, and endothelial cells. EMPS generally circulate at a relatively low level and reflect normal endothelial cell turnover. Elevated circulating levels of EMPs can be identified in a number of illnesses including sickle cell disease, immune-mediated thrombotic syndromes such as antiphospholipid syndrome and heparin-induced thrombocytopenia, diabetes, chronic renal failure, acute coronary syndrome, stroke, venous thromboembolic disease, metabolic syndrome, severe hypertension, paroxysmal nocturnal hemoglobinuria, and multiple sclerosis. The functional roles that may be played by endothelial microparticles are diverse and include neutrophil activation, chemotactic attraction of leukocytes, platelet aggregation, generation of thrombin (in vitro) and superoxide anions, stimulation of endothelial proliferation, induction of angiogenesis, MMP-2 and MMP-9 expression enabling vascular invasion of the basement membrane, and carrying of endothelial proteins and protein C.

Given the importance of the endothelium in the pathogenesis of sepsis, we propose to examine the role of endothelial-derived microparticles (EMPs) as a biomarker in sepsis.

Conditions

Systemic Inflammatory Response Syndrome

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Test Cohort

EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.

No interventions assigned to this group

Validation Cohort

EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Adults age 18 and older
• Clinician-suspected diagnosis of sepsis
• Willingness of subject or Legally Authorized Representative (LAR) to participate in the study

Exclusion Criteria

• Desire to forego life-sustaining therapy
• Trauma or surgical subjects
• Pregnancy
• Subjects who, in the opinion of the treating physician and/or investigator, would be at increased risk by the additional blood draw, for instance, subjects with severe anemia, or subjects with anemia who are unwilling or unable to receive blood transfusions

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hamad Medical Corporation

INDUSTRY

Sponsor Role: collaborator

Weill Medical College of Cornell University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ronald G Crystal, MD

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Locations

Weill Cornell Medical College

New York, New York, United States

Hamad Medical Corporation

Doha, , Qatar

Countries

United States; Qatar

Other Identifiers

NPRP 6-1348-3-321

Identifier Type: OTHER

Identifier Source: secondary_id

13-00309

Identifier Type: OTHER

Identifier Source: secondary_id

1305013944

Identifier Type: -

Identifier Source: org_study_id